The judge who found J&J’s pelvic mesh implants defective in a high stakes class action ruling mde a “pervasive error” in disregarding the knowledge and views of the applicants’ doctors, an appeals court has heard.
The Federal Court has once again sided with the Commissioner of Patents in a challenge to a ruling that patents for a computer-implemented invention did not describe a manner of manufacture and should be revoked.
The High Court will hand down its ruling Wednesday in a high-stakes case between ASIC and Westpac that is expected to clarify the line between personal and general financial advice.
The wealthy owners of a Melbourne shoe manufacturer are taking a unit of property developer JD Group to trial this week, alleging “artist impressions” of a nearly $10 million off-the-plan high rise inner city apartment were misleading and deceptive.
Venture capitalist Dr Elaine Stead has been awarded $280,000 in her defamation case against the Nine-owned Australian Financial Review after the Federal Court found she suffered hurt and damage to her reputation through a “targeted campaign of offensive mockery” about her role in collapsed investment firm Blue Sky Alternative Investments.
Drug giant Merck Sharp & Dohme has brought a cross appeal in its long-running intellectual property dispute with Pfizer’s Wyeth over the top selling Prevnar 13 pneumococcal vaccine.
Botox maker Allergan has appealed a court judgment tossing most of trade mark case against an Australian cosmetics company that sells topical creams as Botox alternatives.
Trial is set to begin February 2 in a $100 million shareholder class action against Woolworths over a February 2015 profit downgrade that allegedly led to a drop in the company’s share price.
Building products supplier Wagners has successfully challenged a Queensland Supreme Court judgment ruling in favour of Boral in a high-stakes cement supply dispute between the construction giants.
Pfizer unit Wyeth is seeking to overturn part of a judge’s decision in its high-stakes patent dispute with Merck Sharp & Dohme that found claims in two of its patents relating to the blockbuster Prevnar 13 pneumococcal vaccine were invalid.